REDWOOD CITY, Calif., Jan. 20, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of the first clinical decision making study of the Oncotype DX® colon cancer test that shows that Recurrence Score® (RS) result has a significant impact on treatment recommendations for stage II colon cancer patients. The data, to be presented at the 2012 Gastrointestinal (GI) Cancers Symposium, demonstrate that knowledge of a patient's Recurrence Score changes medical oncologists' treatment recommendations in 29 percent of cases, further confirming the clinical utility of using Oncotype DX as an independent predictor of recurrence in stage II colon cancer. These results are also consistent with the change rate of approximately 30 percent that has been observed in studies evaluating the impact of the Oncotype DX breast cancer test on treatment decisions in early-stage breast cancer patients.
"The Oncotype DX colon cancer test was made available in 2010 based on results from the landmark QUASAR study and is designed to help physicians optimize care for stage II colon cancer patients by analyzing the underlying biology of their individual tumors," said Steven Shak, M.D., chief medical officer of Genomic Health. "These new results support our efforts to gain broad reimbursement coverage and increase patient access, and highlight the independent value beyond conventional measures that the test provides to physicians, patients and payors."
To characterize the impact of the Oncotype DX test on adjuvant treatment recommendations in stage II colon cancer, U.S. medical oncologists who had used the test on three or more patients participated in a survey to assess how the Recurrence Score impacted their treatment decisions. Out of the 92 patients who had treatment recommendations b
|SOURCE Genomic Health, Inc.|
Copyright©2010 PR Newswire.
All rights reserved